Distinct tumorigenic potential of abl and raf in B cell neoplasia: Abl activates the IL-6 signaling pathway

Immunity

Volumn 5, Issue 1, 1996, Pages 81-89

  Hilbert, David M ^a   Migone, Thi Sau ^b   Kopf, Manfred ^c   Leonard, Warren J ^b   Rudikoff, Stuart ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c BASEL INSTITUTE FOR IMMUNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PRISTANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; CONTROLLED STUDY; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PLASMACYTOMA; PRIORITY JOURNAL; RETROVIRUS; SIGNAL TRANSDUCTION;

EID: 0030200982     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(00)80312-X     Document Type: Article

References (77)

1. Akira, S., Nishio, Y., Inoue, M., Wang, X.J., Wei, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., and Kishimoto, T. (1994). Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77, 63-71.
2. Anderson, P.N., and Potter, M. (1969). Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature 222, 994-995.
3. Bast, E.J., Van Camp, B., Reynaert, P., Wiringa, G., and Ballieux, R.E. (1982). Idiotypic peripheral blood lymphocytes in monoclonal gammopathy. Clin. Exp. Immunol. 47, 677-682.
4. Beagley, K.W., Eldridge, J.H., Lee, F., Kiyono, H., Everson, M.P., Koopman, W.J., Hirano, T., Kishimoto, T., and McGhee, J.R. (1989). Interleukins and IgA synthesis: human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J. Exp. Med. 169, 2133-2148.
5. Bergui, L., Schena, M., Gaidano, G., Riva, M., and Caligaris-Cappio, F. (1989). Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J. Exp. Med. 170, 613-618.
6. Billadeau, D., Quam, L., Thomas, W., Kay, N., Greipp, P., Kyle, R., Oken, M.M., and Van Ness, B. (1992). Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 80, 1818-1824.
7. Billadeau, D., Ahmann, G., Greipp, P., and Van Ness, B. (1993). The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J. Exp. Med. 178, 1023-1031.
8. Brosh, N., Sternberg, D., Honigwachs-Sha'anani, J., Lee, B.C., ShavTal, Y., Tzehoval, E., Shulman, L.M., Toledo, J., Hacham, Y., and Carmi, P. (1995). The plasmacytoma growth inhibitor restrictin-P is an antagonist of interleukin 6 and interleukin 11: identification as a stroma-derived activin A. J. Biol. Chem. 270, 29594-29600.
9. Cassel, A., Leibovitz, N., Hornstein, L., Quitt, M., and Aghai, E. (1990). Evidence for the existence of circulating monoclonal B-lymphocytes in multiple myeloma patients. Exp. Hematol. 18, 1171-1173.
10. Danial, N.N., Pernis, A., and Rothman, P.B. (1995). Jak-STAT signaling induced by the v-abl oncogene. Science 269, 1875-1877.
11. de Hon, F.D., Ehlers, M., Rose-John, S., Ebeling, S.B., Bos, H.K., Aarden, L.A., and Brakenhoff, J.P. (1994). Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells. J. Exp. Med. 180, 2395-2400.
12. Degrassi, A., Hilbert, D.M., Rudikoff, S., Anderson, A.O., Potter, M., and Coon, H.G. (1993). In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc. Natl. Acad. Sci. USA 90, 2060-2064.
13. Franz, W.M., Berger, P., and Wang, J.Y. (1989). Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J. 8, 137-147.
14. Goga, A., McLaughlin, J., Pendergast, A.M., Parmar, K., Muller, A., Rosenberg, N., and Witte, O.N. (1993). Oncogenic activation of c-ABL by mutation within its last exon. Mol. Cell Biol. 13, 4967-4975.
15. Hartman, D.A., Ochalski, S.J., and Carlson, P.P. (1995). The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A. Inflam. Res. 44, 269-274.
16. Henttinen, T., Levy, D.E., Silvennoinen, O., and Hurme, M. (1995). Activation of the signal transducer and transcription (STAT) signaling pathway in a primary T cell response: critical role for IL-6. J. Immunol. 155, 4582-4587.
17. Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T., and Kishimoto, T. (1990). Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63, 1149-1157.
18. Hilbert, D.M., Cancro, M.P., Scherle, P.A., Nordan, R.P., Van Snick, J., Gerhard, W., and Rudikoff, S. (1989). T cell derived IL-6 is differentially required for antigen-specific antibody secretion by primary and secondary B cells. J. Immunol. 143, 4019-4024.
19. Hilbert, D.M., Pumphrey, J.G., Troppmair, J., Rapp, U.R., and Rudikoff, S. (1993). Susceptibility and resistance to J3V1 retrovirus-induced murine plasmacytomagenesis in reconstituted severe combined immunodeficient mice. Oncogene 8, 1993-2000.
20. Hilbert, D.M., Shen, M.Y., Rapp, U.R., and Rudikoff, S. (1995a). T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors. Proc. Natl. Acad. Sci. USA 92, 649-655.
21. Hilbert, D.M., Kopf, M., Mock, B.A., Kohler, G., and Rudikoff, S. (1995b). Interleukin 6 is essential for in vivo development of B lineage neoplasms. J. Exp. Med. 182, 243-248.
22. Hitzler, J.K., Martinez-Valdez, H., Bergsagel, D.B., Minden, M.D., and Messner, H.A. (1991). Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood 78, 1996-2004.
23. Jackson, P., and Baltimore, D. (1989). N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J. 8, 449-456.
24. Jensen, G.S., Mant, M.J., Belch, A.J., Berenson, J.R., Ruether, B.A., and Pilarski, L.M. (1991). Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 78, 711-719.
25. Jensen, G.S., Mant, M.J., and Pilarski, L.M. (1992). Sequential maturation stages of monoclonal B lineage cells from blood, spleen, lymph node, and bone marrow from a terminal myeloma patient. Am. J. Hematol. 41, 199-208.
26. Jensen, G.S., Belch, A.R., Mant, M.J., Ruether, B.A., Yacyshyn, B.R., and Pilarski, L.M. (1993). Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. Am. J. Hematol. 43, 29-36.
27. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., and Tanaka, H. (1988). Autocrine generation and requirement of BSF-2/IL-6 for human multiplemyelomas. Nature 332, 83-85.
28. King, M.A., and Nelson, D.S. (1989). Tumor cell heterogeneity in multiple myeloma: antigenic, morphologic, and functional studies of cells from blood and bone marrow. Blood 73, 1925-1935.
29. Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., and Bataille, R. (1989). Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73, 517-526.
30. Klein, B., Wijdenes, J., Zhang, X.G., Jourdan, M., Boiron, J.M., Brochier, J., Liautard, J., Merlin, M., Clement, C., and Morel-Fournier, B. (1991). Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78, 1198-1204.
31. Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., and Kohler, G. (1994). Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368, 339-342.
32. Kubagawa, H., Vogler, L.B., Capra, J.D., Conrad, M.E., Lawton, A.R., and Cooper, M.D. (1979). Studies on the clonal origin of multiple myeloma: use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J. Exp. Med. 150, 792-807.
33. Kurie, J.M., Morse, H.C., Principato, M.A., Wax, J.S., Troppmair, J., Rapp, U.R., Potter, M., and Mushinski, J.F. (1990). v-myc and v-raf act synergistically to induce B-cell tumors in pristane-primed adult BALBC mice. Oncogene 5, 577-582.
34. Lapena, P., Prieto, A., Garcia-Suarez, J., Reyes, E., San Miguel, J., Jorda, J., and Alvarez-Mon, M. (1996). Increased production of interleukin-6 by T lymphocytes from patients with multiple myeloma. Exp. Hematol. 24, 26-30.
35. Largaespada, D.A., Kaehler, D.A., Mishak, H., Weissinger, E., Potter, M., Mushinski, J.F., and Risser, R. (1992). A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas. Oncogene 7, 811-819.
36. Lin, J.X., Migone, T.S., Tsang, M., Friedmann, M., Weatherbee, J.A., Zhou, L., Yamauchi, A., Bloom, E.T., Mietz, J., John, S., and Leonard W.J. (1995). The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2, 331-339.
37. Lokhorst, H.M., Lamme, T., de Smet, M., Klein, S., de Weger, R.A., van Oers, R., and Bloem, A.C. (1994). Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 84, 2269-2277.
38. Maeda, M., Arima, N., Daitoku, Y., Kashihara, M., Okamoto, H., Uchiyama, T., Shirono, K., Matsuoka, M., Hattori, T., and Takatsuki, K. (1987). Evidence for the interleukin-2 dependent expansion of leukemic cells in adult T cell leukemia. Blood 70, 1407-1411.
39. Martin, F., Toniatti, C., Salvati, A.L., Ciliberto, G., Cortese, R., and Sollazzo, M. (1996). Coupling protein design and in vitro selection strategies: improving specificity and affinity of a designed beta-protein IL-6 antagonist. J. Mol. Biol. 255, 86-97.
40. Matsuda, T., Yamanaka, Y., and Hirano, T. (1994). Interleukin-6-induced tyrosine phosphorylation of multiple proteins in murine hematopoietic lineage cells. Biochem. Biophys. Res. Commun. 200, 821-828.
41. Merwin, R.M., and Algire, G.H. (1959). Induction of plasma cell neoplasms and fibrosarcomas in BALB/c mice carrying diffusion chambers. Proc. Soc. Exp. Biol. Med. 101, 437-439.
42. Migone, T.S., Lin, J.X., Cereseto, A., Mulloy, J.C., O'Shea, J.J., Franchini, G., and Leonard, W.J. (1995). Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269, 79-81.
43. Mock, B.A., Krall, M.M., and Dosik, J.K. (1993). Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis. Proc. Natl. Acad. Sci. USA 90, 9499-9503.
44. Moelling, K., Heimann, B., Beimling, P., Rapp, U.R., and Sander, T. (1984). Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins. Nature 312, 558-561.
45. Nakajima, K., Matsuda, T., Fujitani, Y., Kojima, H., Yamanaka, Y., Nakae, K., Takeda, T., and Hirano, T. (1995). Signal transduction through IL-6 receptor: involvement of multiple protein kinases, stat factors, and a novel H7-sensitive pathway. Ann. NY Acad. Sci. 762, 55-70.
46. Narazaki, M., Witthuhn, B.A., Yoshida, K., Silvennoinen, O., Yasukawa, K., Ihle, J.N., Kishimoto, T., and Taga, T. (1994). Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc. Natl. Acad. Sci. USA 91, 2285-2289.
47. Nordan, R.P., and Potter, M. (1986). A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 233, 566-569.
48. Okano, A., Suzuki, C., Takatsuki, F., Akiyama, Y., Koike, K., Ozawa, K., Hirano, T., Kishimoto, T., Nakahata, T., and Asano, S. (1989). In vitro expansion of the murine pluripotent hemopoietic stem cell population in response to interleukin 3 and interleukin 6: application to bone marrow transplantation. Transplantation 48, 495-498.
49. Osterborg, A., Steinitz, M., Lewin, N., Bergenbrant, S., Holm, G., Lefvert, A.K., and Mellstedt, H. (1991). Establishment of idiotype bearing B-lymphocyte clones from a patient with monoclonal gammopathy. Blood 78, 2642-2649.
50. Palumbo, A., Bruno, B., Boccadoro, M., and Pileri, A. (1995). Interferon-gamma in multiple myeloma. Leuk. Lymphoma. 18, 215-219.
51. Potter, M. (1984). Genetics of susceptibility to plasmacytoma development in BALB/c mice. Cancer Surv. 3, 247-264.
52. Potter, M., and Boyce, C. (1962). Induction of plasma cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature 193, 1086-1087.
53. Potter, M., and Wax, J.S. (1983). Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens. J. Natl. Cancer Inst. 71, 391-395.
54. Potter, M., and Wiener, F. (1992). Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations. Carcinogenesis 13, 1681-1697.
55. Potter, M., Morrison, S., Wiener, F., Zhang, X.K., and Miller, F.W. (1994a). Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice. J. Natl. Cancer Inst. 86, 1058-1065.
56. Potter, M., Mushinski, E.B., Wax, J.S., Hartley, J., and Mock, B.A. (1994b). Identification of two genes on chromosome 4 that determine resistance to plasmacytoma induction in mice. Cancer Res. 54, 969-975.
57. Ramsay, A.J., Husband, A.J., Ramshaw, I.A., Bao, S., Matthaei, K.I., Koehler, G., and Kopf, M. (1994). The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264, 561-563.
58. Savino, R., Ciapponi, L., Lahm, A., Demartis, A., Cabibbo, A., Toniatti, C., Delmastro, P., Altamura, S., and Ciliberto, G. (1994). Rational design of a receptor super-antagonist of human interleukin-6. EMBO J. 13, 5863-5870.
59. Sawyers, C.L. (1992). The bcr-abl gene in chronic myelogenous leukaemia. Cancer Surv. 15, 37-51.
60. Sawyers, C.L., McLaughlin, J., and Witte, O.N. (1995). Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J. Exp. Med. 181, 307-313.
61. Shimizu, S., Yoshioka, R., Hirose, Y., Sugai, S., Tachibana, J., and Konda, S. (1989). Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon beta 2)-dependent human bone marrow-derived myeloma cell lines. J. Exp. Med. 169, 339-344.
62. Silva, S., Sugiyama, H., Babonits, M., Wiener, F., and Klein, G. (1991). Differential susceptibility of BALB/c and DBA/2 cells to plasmacytoma induction in reciprocal chimeras. Int. J. Cancer 49, 224-228.
63. Stahl, N., Boulton, T.G., Farruggella, T., Ip, N.Y., Davis, S., Witthuhn, B.A., Quelle, F.W., Silvennoinen, O., Barbieri, G., and Pellegrini, S. (1994). Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 263, 92-95.
64. Sugiyama, H., Wiener, F., Babonits, M., Silva, S., Hirano, T., Kishimoto, T., and Klein, G. (1991). v-abl does not abolish IL-6 requirement by murine plasmacytoma cells. Int. J. Cancer 48, 234-238.
65. Suzuki, H., Yasukawa, K., Saito, T., Goitsuka, R., Hasegawa, A., Ohsugi, Y., Taga, T., and Kishimoto, T. (1992). Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur. J. Immunol. 22, 1989-1993.
66. Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., and Kishimoto, T. (1989). Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58, 573-581.
67. Takatsuki, F., Okano, A., Suzuki, C., Chieda, R., Takahara, Y., Hirano, T., Kishimoto, T., Hamuro, J., and Akiyama, Y. (1988). Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo. J. Immunol. 141, 3072-3077.
68. Troppmair, J., Potter, M., Wax, J.S., and Rapp, U.R. (1989). An altered v-raf is required in addition to v-myc in J3V1 virus for acceleration of murine plasmacytomagenesis. Proc. Natl. Acad. Sci. USA 86, 9941-9945.
69. Uchiyama, H., Barut, B.A., Mohrbacher, A.F., Chauhan, D., and Anderson, K.C. (1993). Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82, 3712-3720.
70. Van Riet, I., Heirman, C., Lacor, P., De Waele, M., Thielemans, K., and Van Camp, B. (1989). Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies. Br. J. Haematol. 73, 289-295.
71. Van Snick, J., Vink, A., Cayphas, S., and Uyttenhove, C. (1987). Interleukin-HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas. J. Exp. Med. 165, 641-649.
72. Vink, A., Coulie, P., Warnier, G., Renauld, J.C., Stevens, M., Donckers, D., and Van Snick, J. (1990). Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J. Exp. Med. 172, 997-1000.
73. Wang, Y., Morella, K.K., Ripperger, J., Lai, C.F., Gearing, D.P., Fey, G.H., Campos, S.P., and Baumann, H. (1995). Receptors for interleukin-3 (IL-3) and growth hormone mediate an IL-6-type transcriptional induction in the presence of JAK2 or Stat3. Blood 86, 1671-1679.
74. Wiener, F., Coleman, A., Mock, B.A., and Potter, M. (1995). Nonrandom chromosomal change (trisomy 11) in murine plasmacytomas induced by an ABL-MYC retrovirus. Cancer Res. 55, 1181-1188.
75. Yamasaki, K., Taga, T., Hirata, Y., Yawata, H., Kawanishi, Y., Seed, B., Taniguchi, T., Hirano, T., and Kishimoto, T. (1988). Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 241, 825-828.
76. Zhang, X.G., Gaillard, J.P., Robillard, N., Lu, Z.Y., Gu, Z.J., Jourdan, M., Boiron, J.M., Bataille, R., and Klein, B. (1994). Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83, 3654-3663.
77. Zhong, Z., Wen, Z., and Darnell, J.E., Jr. (1994). Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264, 95-98.